Medpace Hldgs — Business Overview

What does Medpace do?

Medpace is a contract research organization (CRO) that manages clinical trials on behalf of drug and device makers. A CRO is essentially an outsourced research department — instead of running their own trials, biotech, pharmaceutical, and medical device companies hire Medpace to design, execute, and report on the studies required to get a product approved by regulators like the FDA. Medpace handles the entire process, from Phase I (first-in-human safety studies) through Phase IV (post-approval monitoring).

Medpace operates as a single, integrated business segment rather than multiple divisions. That said, the company offers a broad range of services under one roof, including clinical trial management, patient recruitment, regulatory affairs, medical writing, biostatistics, pharmacovigilance (drug safety monitoring), and laboratory services (central, bioanalytical, and core labs). It also runs its own Phase I clinics on its campus in Cincinnati, Ohio. This "full-service" model under one roof is central to how Medpace positions itself competitively.

How does Medpace make money?

Medpace earns revenue by charging clients fees for running their clinical trials. Clients — primarily small and mid-sized biopharmaceutical companies — contract with Medpace to manage some or all stages of their clinical development programs. Revenue is generally tied to the scope and duration of these contracts. The company also maintains a backlog (contracted work not yet completed), which provides visibility into future revenue.

In some cases, Medpace takes on financial risk by making strategic investments in clients or offering flexible payment terms. This can include equity stakes in smaller biotech companies or fee-financing arrangements, meaning the company occasionally has skin in the game beyond just a service fee. This approach can deepen client relationships but introduces some payment risk.

What market does Medpace operate in?

Medpace competes in the global Phase I–IV CRO market, which is growing as pharmaceutical companies increasingly outsource their clinical development work. Rather than building and maintaining expensive in-house research infrastructure, drug developers — especially smaller biotechs — find it more efficient to hire specialists like Medpace. This outsourcing trend has been a durable tailwind for the CRO industry.

Medpace's strongest therapeutic areas include Oncology, Metabolic diseases, Cardiology, Antiviral and Anti-infective (AVAI), and Central Nervous System (CNS) disorders — all of which the company describes as among the largest, most complex, and fastest-growing areas of pharmaceutical development. These are not niche categories; they represent the bulk of global drug development spending.

Who are Medpace's main competitors?

The CRO industry is a mix of a few large global players and hundreds of smaller, narrowly focused firms. Medpace's named major competitors include IQVIA Holdings, ICON plc, PPD (now part of Thermo Fisher Scientific), Fortrea, and numerous regional and specialty CROs. The large players have significant scale and global infrastructure; the smaller ones often compete on price or niche expertise.

Medpace differentiates itself through a disciplined full-service model and deep therapeutic expertise, targeting small and mid-sized biotech clients. Rather than fragmenting work across many providers, Medpace keeps everything in-house and uses a proprietary information system called ClinTrak to manage study execution in real time. The company argues this produces faster, higher-quality results. It also embeds medical and scientific experts early in the sales process — not just during execution — which it believes builds stronger client relationships.

The company claims meaningful barriers to entry protect established full-service CROs. Building the therapeutic expertise, regulatory knowledge, global infrastructure, and quality systems required to compete at scale takes years and significant capital. This makes it difficult for smaller regional players to move upmarket, even in a fragmented industry.

Where does Medpace operate?

Medpace has a global footprint, with approximately 6,200 employees across 46 countries as of December 31, 2025, up from roughly 5,900 at the end of 2024. Its operational hub is Cincinnati, Ohio, where its Phase I clinics, bioanalytical laboratory, and corporate headquarters are located.

Its Central Laboratory — which processes biological samples for clinical trials — operates across four locations: Cincinnati (USA), Leuven (Belgium), Shanghai (China), and Singapore. This geographic spread allows Medpace to support trials running simultaneously across multiple regions and time zones.

Clinical trials conducted outside the United States expose Medpace to a patchwork of local regulations. Trials in the EU are overseen by the European Medicines Agency (EMA) and member-state authorities; in the UK by the MHRA; in Canada by Health Canada; and by equivalent bodies across Asia and Latin America. The filing notes that non-US trials may also fall under FDA oversight if they are part of an application seeking US approval, adding a layer of regulatory complexity to the company's international operations.